Business Description
Ono Pharmaceutical Co Ltd
ISIN : JP3197600004
Description
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a world-wide business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.12 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.21 | |||||
| Debt-to-EBITDA | 1.14 | |||||
| Interest Coverage | 27 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 4.31 | |||||
| Beneish M-Score | -2.91 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 19.1 | |||||
| 3-Year EBITDA Growth Rate | 17.5 | |||||
| 3-Year EPS without NRI Growth Rate | 20.8 | |||||
| 3-Year FCF Growth Rate | 20.3 | |||||
| 3-Year Book Growth Rate | 9.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -12.18 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 1.37 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.22 | |||||
| Quick Ratio | 2.8 | |||||
| Cash Ratio | 1.45 | |||||
| Days Inventory | 149.83 | |||||
| Days Sales Outstanding | 106.55 | |||||
| Days Payable | 172.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Payout Ratio | 0.41 | |||||
| 3-Year Dividend Growth Rate | 21.1 | |||||
| 3-Year Average Share Buyback Ratio | 2 | |||||
| Shareholder Yield % | 0.89 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.38 | |||||
| Operating Margin % | 24.53 | |||||
| Net Margin % | 19.64 | |||||
| FCF Margin % | 19.2 | |||||
| ROE % | 12.13 | |||||
| ROA % | 10.15 | |||||
| ROIC % | 13.65 | |||||
| 3-Year ROIIC % | 116.9 | |||||
| ROC (Joel Greenblatt) % | 54.55 | |||||
| ROCE % | 14.84 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 9.44 | |||||
| Forward PE Ratio | 16.26 | |||||
| PE Ratio without NRI | 9.44 | |||||
| Shiller PE Ratio | 13.05 | |||||
| Price-to-Owner-Earnings | 8.3 | |||||
| PEG Ratio | 0.46 | |||||
| PS Ratio | 1.86 | |||||
| PB Ratio | 1.14 | |||||
| Price-to-Tangible-Book | 2.15 | |||||
| Price-to-Free-Cash-Flow | 9.79 | |||||
| Price-to-Operating-Cash-Flow | 8.28 | |||||
| EV-to-EBIT | 7.09 | |||||
| EV-to-Forward-EBIT | 7.51 | |||||
| EV-to-EBITDA | 6.18 | |||||
| EV-to-Forward-EBITDA | 6.71 | |||||
| EV-to-Revenue | 1.81 | |||||
| EV-to-Forward-Revenue | 2.38 | |||||
| EV-to-FCF | 9.52 | |||||
| Price-to-Projected-FCF | 0.53 | |||||
| Price-to-DCF (Earnings Based) | 0.3 | |||||
| Price-to-DCF (FCF Based) | 0.31 | |||||
| Price-to-Median-PS-Value | 0.39 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.54 | |||||
| Price-to-Graham-Number | 0.95 | |||||
| Price-to-Net-Current-Asset-Value | 6.51 | |||||
| Earnings Yield (Greenblatt) % | 14.1 | |||||
| FCF Yield % | 10.28 | |||||
| Forward Rate of Return (Yacktman) % | 26.08 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ono Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 58,665.598 | ||
| EPS (TTM) (MXN) | 24.241 | ||
| Beta | 0 | ||
| Volatility % | 1.97 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (MXN) | 0 | ||
| 20-Day SMA (MXN) | 341.69 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (MXN) | 341.69 - 341.69 | ||
| Shares Outstanding (Mil) | 469.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ono Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ono Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ono Pharmaceutical Co Ltd Frequently Asked Questions
What is Ono Pharmaceutical Co Ltd(MEX:4528)'s stock price today?
The current price of MEX:4528 is MXN341.69. The 52 week high of MEX:4528 is MXN341.69 and 52 week low is MXN341.69.
When is next earnings date of Ono Pharmaceutical Co Ltd(MEX:4528)?
The next earnings date of Ono Pharmaceutical Co Ltd(MEX:4528) is .
Does Ono Pharmaceutical Co Ltd(MEX:4528) pay dividends? If so, how much?
Ono Pharmaceutical Co Ltd(MEX:4528) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers